Navigation Links
NIH tools facilitate matching cancer drugs with gene targets
Date:7/15/2012

A new study details how a suite of web-based tools provides the research community with greatly improved capacity to compare data derived from large collections of genomic information against thousands of drugs. By comparing drugs and genetic targets, researchers can more easily identify pharmaceuticals that could be effective against different forms of cancer.

The newly updated software, called CellMiner, was built for use with the NCI-60, one of the most widely utilized collections of cancer cell samples employed in the testing of potential anti-cancer drugs. The tools, available free, provide rapid access to data from 22,379 genes catalogued in the NCI-60 and from 20,503 previously analyzed chemical compounds, including 102 U.S. Food and Drug Administration-approved drugs.

The study, written by the scientists that developed the tools at the National Cancer Institute (NCI), part of the National Institutes of Health, appeared in the July 16, 2012, issue of Cancer Research.

"Previously you would have to hire a bioinformatics team to sort through all of the data, but these tools put the entire database at the fingertips of any researcher," explained Yves Pommier, M.D., Ph.D., of the NCI's Center for Cancer Research. "These tools allow researchers to analyze drug responses as well as make comparisons from drug to drug and gene to gene."

Genomic sequencing and analysis have become increasingly important in biomedicine, but they are yielding data sets so vast that researchers may find it difficult to access and compare them. As new technologies emerge and more data are generated, tools to facilitate the comparative study of genes and potentially promising drugs will be of even greater importance. With the new tools, available at http://discover.nci.nih.gov/cellminer, researchers can compare patterns of drug act
'/>"/>

Contact: NCI Press Office
ncipressofficers@mail.nih.gov
301-496-6641
NIH/National Cancer Institute
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
2. Mayo Clinic: Standard heart disease risk tools underrate danger in rheumatoid arthritis
3. Hospitals communication during residency matching may put stress on OB-GYN doctors-in-training
4. Lung nodule matching software dramatically increases radiologists efficiency
5. Study Suggests Vaccine May Help Kids With Brain Cancer
6. New Stool Test Might Aid in Early Detection of Colon Cancer
7. Study reveals how cancer drug causes diabetic-like state
8. How a cancer drug leads to diabetes
9. You Survived Cancer: Now Pay Attention to Your Overall Health
10. New drug prevents spread of human prostate cancer cells
11. Eliminating the good cholesterol receptor may fight breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
NIH tools facilitate matching cancer drugs with gene targets
(Date:7/6/2015)... ... 06, 2015 , ... Dr. Lawrence Green is now offering the newly FDA-approved ... is a non-surgical method to dissolve fat cells and is the first of its ... under the chin, commonly known as a double chin. Dr. Green participated in clinical ...
(Date:7/6/2015)... ... July 06, 2015 , ... Diabetes affects many of us and the Glycemic ... have diabetes, the majority of which are Type 2. However, eight million do not ... in three, have prediabetes (abnormally high blood sugar levels). Without reductions in blood sugar ...
(Date:7/5/2015)... ... July 06, 2015 , ... ... is excited to announce the next generation of PrimeStar Individual Dental Insurance. Beginning ... now include two network options—Maximum Allowable Charge (MAC) and usual, customary and reasonable ...
(Date:7/5/2015)... Philadelphia, PA (PRWEB) , ... July 05, 2015 ... ... engineer of patented products, announces the Weed Master, a landscaping invention that ... is worth $75 billion US dollars," says Scott Cooper, CEO and Creative Director ...
(Date:7/4/2015)... ... July 05, 2015 , ... Dating a real millionaire ... the best online millionaire dating service and strives to remove the worries from meeting ... 1 millionaire dating app of 2015 and readers have responded with excitement. ...
Breaking Medicine News(10 mins):Health News:Rockville, MD Practice Now Offering New FDA-Approved Non-Surgical Double Chin Treatment 2Health News:115 Million in the U.S. could beat diabetes with the help of a new app 2Health News:Security Life Insurance Company of America Launches the Next Generation of PrimeStar Individual Dental Insurance Plans 2Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 2Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 3Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 4Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 5Health News:MillionaireMatchapp.com Publishes the Best Millionaire Dating App and Official Dating Site Reviews 2015 2
... service (EMS) providers in the United States assess ... Only 5 to 10 percent of people who ... cardiopulmonary resuscitation (CPR) provided by prehospital EMS providers ... The Resuscitation Outcomes Consortium (ROC) is the largest ...
... as 34 weeks, potentially adding to preemie delivery rate, experts say ... the rate of preterm deliveries continues to climb in the United ... women are confused about what constitutes a full-term birth in the ... study considered a baby born at 34 to 36 weeks of ...
... flu , FRIDAY, Nov. 20 (HealthDay News) -- Canadian ... to develop severe cases of H1N1 flu than seasonal flu. ... for admission with pandemic H1N1 influenza, present in 21 percent ... Allen and fellow researchers from the Hospital for Sick Children ...
... ... Services Task Force. These guidelines may be cost-effective, but they come at the price of ... ... published in the current issue of the Annals of Internal Medicine, has set off a ...
... , , SPRINGFIELD, Mo., Nov. 20 ... Missouri regions will now have the option to choose ... between Missouri Consolidated Health Care Plan (MCHCP) and Mercy ... regions include the following counties: Barry, Barton, Cedar, Christian, ...
... , , LOS ... African American Families, The Wall/Las Memorias, Latina Breast Cancer Agency, ... today sent a letter to Blue Shield of California calling ... , The letter to Blue Shield specifically calls for an ...
Cached Medicine News:Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3Health News:Many Women Miscalculate Time to Full-Term Birth 2Health News:Many Women Miscalculate Time to Full-Term Birth 3Health News:Many Women Miscalculate Time to Full-Term Birth 4Health News:New Breast Cancer Recommendation May Cost Lives While Saving Money 2Health News:New Breast Cancer Recommendation May Cost Lives While Saving Money 3Health News:Missouri Consolidated Health Care Plan Provides Mercy Health Plans Option 2Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 2Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 3Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 4
(Date:7/6/2015)... /PRNewswire/ -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD ... chain in China based on ... its board of directors has received a preliminary non-binding ... Zhang , chairman of the board of directors of ... investment vehicle wholly owned by Mr. Zhang(" Neptunus Holding ...
(Date:7/4/2015)... BARCELONA , Spanje, July 4, 2015 ... SIR-Spheres® Y-90 harsmicrosferen aan eerstelijns chemotherapie voor ... de lever (mCRC) verlengt de progressievrije overleving ... met niet-resectabele, gemetastaseerde colorectale kanker (mCRC) die ... grootste verbetering gezien in progressievrije overleving (PFS) ...
(Date:7/3/2015)... , July 4, 2015 ... epidemics of hypertension, diabetes and thyroid disorders in Central ... online educational platforms and a major conference dedicated to ... Manage Diabetes Online , Manage Hypertension ... each developed and operated by EXCEMED - ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 2China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 3China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 4China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 5China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 6Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 2Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 5Combating Three Major Chronic Diseases in Central and South-East Asia With Medical Education 2
... Pharmion,Corporation (Nasdaq: PHRM ) and ... of the first patient in a Phase ... Companies, isotype-selective histone,deacetylase inhibitor (HDACi) product candidate, ... DNA demethylating agent,in patients with relapsed or ...
... Semafore Pharmaceuticals Inc.,today announced that a paper ... 1: 206-215) reports that SF1126, the company,s ... The paper, entitled "A Vascular Targeted ... and Antiangiogenic Activity," is,based on preclinical studies ...
Cached Medicine Technology:Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 2Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 3Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 4Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 5Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 6Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 7Semafore's SF1126 Exhibits Antitumor and Antiangiogenic Activity 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: